KB707 + pembrolizumab

KB707 + pembrolizumab is a combination therapy in clinical development for the treatment of advanced melanoma. **KB707** is a genetically modified, replication-defective herpes simplex virus type 1 that delivers genes encoding interleukin-2 and interleukin-12, aiming to stimulate anti-tumor immune responses. **Pembrolizumab** is a humanized monoclonal antibody targeting programmed cell death protein 1 (PD-1) and acts as an immune checkpoint inhibitor. When combined, this therapy aims to synergistically enhance anti-tumor immunity through viral-mediated cytokine delivery and PD-1 blockade. The combination is under investigation for patients with stage III (unresectable) or stage IV melanoma, often after progression on previous therapies[1][2][3][5].